Tango Therapeutics, Inc. (TNGX) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
March 27, 2023 7:00 AM EDTFast Track Designation granted to TNG462, next-generation MTA-Cooperative PRMT5 inhibitor
Adam Crystal, M.D., Ph.D. appointed President of Research and Development
BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.
2022 was an important year for Tango, as we made critical strides in advancing our programs. We advanced our... More
